๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

The cirrhosis risk score predicts liver fibrosis progression in patients with initially mild chronic hepatitis C

โœ Scribed by Pierre Pradat; Eric Trepo; Andrej Potthoff; Rakesh Bakshi; Bradford Young; Christian Trepo; Robert Lagier; Christophe Moreno; Arnaud Lemmers; Thierry Gustot; Delphine Degre; Michael Adler; Heiner Wedemeyer

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
46 KB
Volume
51
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

A seven-gene signature (cirrhosis risk s
A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C
โœ Moira Marcolongo; Bradford Young; Francesca Dal Pero; Giovanna Fattovich; Laura ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 116 KB ๐Ÿ‘ 1 views

Fibrosis progression is the main determinant of liver disease outcome in chronic hepatitis C, being influenced by environmental and host factors. Recently, a cirrhosis risk score (CRS) based on seven single-nucleotide polymorphisms was proposed as genetic predictor of cirrhosis in hepatitis C. To as

A 7 gene signature identifies the risk o
A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C
โœ Hongjin Huang; Mitchell L. Shiffman; Scott Friedman; Ramasubbu Venkatesh; Natali ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 443 KB ๐Ÿ‘ 1 views

Clinical factors such as age, gender, alcohol use, and age-at-infection influence the progression to cirrhosis but cannot accurately predict the risk of developing cirrhosis in patients with chronic hepatitis C (CHC). The aim of this study was to develop a predictive signature for cirrhosis in Cauca

Final results of a double-blind, placebo
Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-ฮณ1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis
โœ Paul J. Pockros; Lennox Jeffers; Nezam Afdhal; Zachary D. Goodman; David Nelson; ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 383 KB ๐Ÿ‘ 1 views

## Interferon-โฅ1b (IFN-โฅ1b ) is a pleiotropic cytokine that displays antifibrotic, antiviral, and antiproliferative activity. A total of 502 patients with compensated liver disease and an Ishak fibrosis score of 4-6 were randomized in a double-blind, placebo-controlled study, and 488 of these pati

Severity of liver disease predicts the d
Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy
โœ Wassim Chehadeh; Widad Al-Nakib ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 134 KB

## Abstract A higher prevalence of glucose abnormalities has been reported in patients with hepatitis C virus (HCV) infection compared to patients with hepatitis B virus (HBV) infection. However, previous studies considered some confounding factors and ignored others, which might influence the comp

Serum insulin-like growth factor I evalu
Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis : A prospective study
โœ Gherardo Mazziotti; Francesca Sorvillo; Filomena Morisco; Antonella Carbone; Mar ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 108 KB ๐Ÿ‘ 3 views

## Background: Although experimental studies have demonstrated an important role of insulin-like growth factor i (igf-i) in hepatocarcinogenesis, the clinical data about igf-i in patients with hepatocellular carcinoma (hcc) are scarce and controversial. to the authors' knowledge, this is the first